BioCentury | Nov 18, 2020
Product Development

COVID-19 Quick Takes: EMA to require more stringent safety monitoring for vaccines; plus J&J, Clover-Thousand Oaks, Medicago-GSK, Inovio and Synairgen

...VLP (CoVLP, MT-2766) CpG 1018 Interferon beta (IFNB) (AZD9412, SNG001, sng-1, SGN-1) Johnson & Johnson Inovio Pharmaceuticals Inc. Medicago Inc. GlaxoSmithKline plc Dynavax Technologies Corp. Synairgen...
BioCentury | Nov 7, 2020
Targets & Mechanisms

Product profiles that could make interferons effective against COVID-19

...syndrome (ARDS). By contrast, Richard Marsden, CEO of Synairgen plc...
...use of steroids and IFNβ. Marsden said Synairgen’s...
...a 101-patient double-blind Phase II trial of Synairgen’s...
BioCentury | Oct 17, 2020
Deals

Oct. 16 Quick Takes: Dren Bio’s $60M series A; plus Roche, Synairgen, Astellas-iota and more

...estimates, while Tecentriq atezolizumab was roughly in line.Synairgen...
...with heart failure. Consensus estimates provided by FactSet. BC Staff Astellas AtheroChem Synairgen Boehringer...
BioCentury | Jul 21, 2020
Product Development

First inhaled interferon COVID-19 readout bolsters case for class, but more robust data needed

...Data suggesting an inhaled IFNB1 product from Synairgen can reduce the chance a patient with COVID-19...
...if and when the cytokine provides a benefit over standard of care or other antivirals. Synairgen...
...duration of mechanical ventilation. Targets IFNB1 - Interferon-β Elizabeth S. Eaton, Staff Writer Interferon beta (IFNB) (AZD9412, SNG001, sng-1, SGN-1) Synairgen...
BioCentury | Mar 19, 2020
Product Development

Roivant pivots towards ARDS in COVID-19; plus Italian studies of repurposed anti-inflammatories, vaccine updates and more

...which one to bring into the clinic. IMV hasn’t yet determined a clinical development timeline. Synairgen...
...GmbH EUSA Pharma Ltd. CanSino Biologics Inc. Johnson & Johnson BGI Genomics Co. Ltd. U.S. Department of Health and Human Services Synairgen...
BioCentury | Mar 7, 2018
Distillery Techniques

Drug platforms

...Los Angeles, Calif. email: lily.duyushen@gmail.com CONTACT: Ren Sun, same affiliation as above email: rsun@mednet.ucla.edu Jaime De Leon Interferon beta (IFNB) Interferon University...
BioCentury | Dec 20, 2017
Translation in Brief

Diabetes hits a checkpoint

...reverses autoimmune diabetes.” Science Translational Medicine (2017) Mark Zipkin, Staff Writer and Karen Tkach Tuzman, Senior Writer Interferon beta (IFNB) Boston...
BioCentury | Apr 28, 2017
Clinical News

AZD9412: Development discontinued

...reported severe exacerbations could make primary endpoint conclusions difficult” (see BioCentury, Oct. 24, 2016 ). Synairgen...
...16, 2014 ). Synairgen plc (LSE:SNG), Southampton, U.K. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Interferon beta (IFNB)...
...Indication: Treat respiratory virus-induced exacerbations of asthma Endpoint: NA Status: Development discontinued Milestone: NA Chris Lieu AZD9412 SNG001 AstraZeneca plc Synairgen...
BioCentury | Apr 27, 2017
Company News

AZ returns asthma candidate's rights to Synairgen

...respiratory virus-induced exacerbations of asthma did not meet AstraZeneca's predefined progression criteria. In October 2016, Synairgen...
...could make primary endpoint conclusions difficult" (see BioCentury Extra, Oct. 12, 2016) . On Thursday, Synairgen...
...IP-10) and improved lung function as measured by morning peak expiratory flow (p=0.01) vs. placebo. Synairgen...
BioCentury | Jan 6, 2017
Finance

Tiers of disappointment

...issues a complete response letter for Qapzola apaziquone to treat non-muscle invasive bladder cancer (NMIBC) Synairgen...
Items per page:
1 - 10 of 60